Skip to main
TEM

TEM Stock Forecast & Price Target

TEM Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 50%
Buy 20%
Hold 30%
Sell 0%
Strong Sell 0%

Bulls say

Tempus AI Inc has demonstrated significant revenue growth, with total revenue increasing by 84.7% year-over-year, largely driven by a remarkable 117.2% increase in Genomics revenue, which reached $252.9 million. The company is also experiencing a favorable shift in its product mix, as evidenced by expected higher average selling prices (ASPs) from its xF liquid biopsy assay and the xT CDx test, which should enhance margins and profitability. Furthermore, the anticipated signing of additional pharmaceutical contracts and the potential increase in oncology testing volumes following reimbursement for its xM test present a robust opportunity for sustained financial improvement.

Bears say

The financial analysis of Tempus AI Inc reveals underlying concerns regarding the company's profitability and growth trajectory, highlighted by a decline in gross margins from 76.8% in Q3 2024 to 69.7% in Q3 2025. Additionally, the company continues to face significant risks, including competition, regulatory hurdles, and potential difficulties in acquiring and retaining partnerships, all of which pose threats to projected sales growth. Furthermore, with ongoing substantial losses since inception, a high debt burden of $518.8 million, and decreased operating cash flow, Tempus AI's ability to achieve sustainable profitability appears increasingly tenuous.

TEM has been analyzed by 10 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 20% recommend Buy, 30% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Tempus AI Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Tempus AI Inc (TEM) Forecast

Analysts have given TEM a Buy based on their latest research and market trends.

According to 10 analysts, TEM has a Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $84.30, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $84.30, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Tempus AI Inc (TEM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.